• Earlier in April 2026, Ocular Therapeutix reported additional positive Week 52 data from its Phase 3 SOL-1 trial, showing AXPAXLI (OTX-TKI) delivered superior durability, sustained disease control, and a generally well-tolerated safety profile versus aflibercept in treatment‑naïve wet AMD patients.
• The update also highlighted that recent FDA commentary supports the company’s plan to seek approval for AXPAXLI based on this single, well-controlled Phase 3 trial, potentially shortening the path to an NDA filing.
• We’ll now examine how AXPAXLI’s strong one-year durability data and potential single-trial approval route may reshape Ocular Therapeutix’s investment narrative.

The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Ocular Therapeutix Investment Narrative Recap

To own Ocular Therapeutix today, you need to believe AXPAXLI can convert its SOL-1 Phase 3 success into FDA approval and a viable wet AMD franchise before cash needs intensify. The new Week 52 data and clearer path to a single‑trial NDA sharpen the near term regulatory catalyst, but they do not remove the key risk that any FDA pushback or safety concern could still leave a single‑product‑dependent, loss‑making company exposed.

Among recent developments, the planned June 17, 2026 Investor Day stands out, as it will likely frame how management positions the SOL-1 durability data, outlines the NDA timing, and updates expectations for cash runway and commercialization build‑out. For shareholders, that event may help connect the latest AXPAXLI results with practical questions about launch readiness, future spending, and how the company plans to balance growth ambitions with dilution risk.

Ocular Therapeutix's narrative projects $287.1 million revenue and $57.1 million earnings by 2029.

Uncover how Ocular Therapeutix's forecasts yield a $26.00 fair value, a 171% upside to its current price.

Exploring Other Perspectives

Yet while consensus remains cautious about dilution and reliance on AXPAXLI, the most optimistic analysts were already modeling revenue near US$252,000,000 by 2028 and a sharp margin swing, suggesting this new durability update could either reinforce or challenge a much more bullish view of how quickly the story improves if everything goes right, and that is something investors should be aware of...

Compared with the baseline worries about trial or regulatory setbacks, the most bullish analysts leaned into AXPAXLI as a premium, durable asset that could support about US$252,000,000 of revenue by 2028, showing how differently you might weigh the same SOL-1 news when you explore alternative viewpoints.

Explore 5 other fair value estimates on Ocular Therapeutix - why the stock might be worth just $18.00!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Ocular Therapeutix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ocular Therapeutix's overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 26 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.